Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Hanni Stoklosa, MD, MPH, Marti MacGibbon, CADC-II, ACRPS, and Joseph Stoklosa, MD
Clinicians diagnosing and treating potentially trafficked patients with co-occurring addiction and mental illness should guard against expressing negative biases.
AMA J Ethics. 2017;19(1):23-24. doi:
10.1001/journalofethics.2017.19.1.ecas3-1701.
Carrie A. Bohnert, MPA, Aaron W. Calhoun, MD, and Olivia F. Mittel, MD, MS
Research and training are needed so that physicians are able to identify human trafficking victims and refer them to appropriate trauma-informed treatment.
AMA J Ethics. 2017;19(1):35-42. doi:
10.1001/journalofethics.2017.19.1.ecas4-1701.
Mortality rates for breast cancer are higher where treatments are unavailable and unaffordable. Though less effective, breast examination could be a good screening approach.
AMA J Ethics. 2020;22(2):E93-101. doi:
10.1001/amajethics.2020.93.
Martin Bricknell, PhD, David Whetham, PhD, Richard Sullivan, PhD, and Peter Mahoney, PhD
International humanitarian law obliges clinicians to coordinate with local civilian, military, and nongovernment organizations, and implementation isn't easy.
AMA J Ethics. 2022;24(6):E472-477. doi:
10.1001/amajethics.2022.472.